Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.40 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | AURKA | O14965 | 1/20 | 0.39 |
| ▸ | PIM1 | P11309 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 2/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | SCD | O00767 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1896858 | 0.87 | LMNA (0.53) | LMNAFFAR1FFAR4NPSR1NR3C1 | |
| SCHEMBL1325354 | 0.84 | LMNA (0.51) | LMNAFFAR1FFAR4NPSR1NR3C1 | |
| SCHEMBL2772989 | 0.84 | LMNA (0.51) | LMNAFFAR1FFAR4NPSR1NR3C1 | |
| SCHEMBL27930079 | 0.83 | LMNA (0.50) | LMNAFFAR1FFAR4NPSR1TRPM8 | |
| SCHEMBL22187040 | 0.81 | LMNA (0.46) | LMNAFFAR1FFAR4NPSR1NR3C1 | |
| SCHEMBL665075 | 0.80 | LMNA (0.48) | LMNAFFAR1FFAR4NPSR1NR3C1 | |
| SCHEMBL28977221 | 0.80 | LMNA (0.48) | LMNAFFAR1FFAR4NPSR1NR3C1 | |
| SCHEMBL17439454 | 0.80 | LMNA (0.48) | LMNAFFAR1FFAR4NPSR1NR3C1 | |
| SCHEMBL1458950 | 0.80 | LMNA (0.57) | LMNAFFAR1FFAR4NPSR1NR3C1 | |
| SCHEMBL1143153 | 0.79 | AURKA (0.51) | LMNANPSR1NPC1RAB9AAURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1857108-B1 | PREVENTIVE OR THERAPEUTIC AGENT FOR HERPESVIRUS-RELATED DISEASE | ASTELLAS PHARMA INC (JP) | 2010-12-08 | — | — | EP | disclosed |
| EP-1844775-B1 | THERAPEUTIC AGENT FOR THE TREATMENT OF HERPES PROGENITALIS AFTER DEVELOPMENT OF LESIONS | ASTELLAS PHARMA INC (JP) | 2010-08-11 | — | — | EP | disclosed |
| EP-1844776-B1 | AGENT FOR PREVENTION/TREATMENT OF DISEASE CAUSED BY ACYCLOVIR-RESISTANT HERPESVIRUS | ASTELLAS PHARMA INC (JP) | 2010-04-28 | — | — | EP | disclosed |
| US-20090048310-A1 | AGENT FOR PREVENTION/TREATMENT OF DISEASE CAUSED BY ACYCLOVIR-RESISTANT HERPESVIRUS | ASTELLAS PHARMA INC. (JP) | 2009-02-19 | — | — | US | disclosed |
| US-20090042915-A1 | PREVENTIVE OR THERAPEUTIC AGENT FOR HERPESVIRUS-RELEATED DISEASE | ASTELLAS PHARMA INC. (JP) | 2009-02-12 | — | — | US | disclosed |
| US-20090030049-A1 | MEDICAMENT FOR GENITAL HERPES | ASTELLAS PHARMA INC. (JP) | 2009-01-29 | — | — | US | disclosed |
| US-7465748-B2 | Antiherpesvirus drugs; great pharmacokinetics, good antivirus activity when administered orally at a low dose, high safety profile, less mutagenic concerns; N-(2,6-dimethylphenyl)-N-(2-{[4-(1,3-oxazol-4-yl)phenyl]amino)-2-oxoethyl)tetrahydro-2H-thiopyran-4-carboxamide 1,1-dioxide | ASTELLAS PHARMA INC. (JP) | 2008-12-16 | — | — | US | disclosed |
| EP-1857108-A1 | PREVENTIVE OR THERAPEUTIC AGENT FOR HERPESVIRUS-RELATED DISEASE | Astellas Pharma Inc. (JP) | 2007-11-21 | — | — | EP | disclosed |
| EP-1844776-A1 | AGENT FOR PREVENTION/TREATMENT OF DISEASE CAUSED BY ACYCLOVIR-RESISTANT HERPESVIRUS | Astellas Pharma Inc. (JP) | 2007-10-17 | — | — | EP | disclosed |
| EP-1844775-A1 | THERAPEUTIC AGENT FOR HERPES PROGENITALIS | Astellas Pharma Inc. (JP) | 2007-10-17 | — | — | EP | disclosed |
| US-20060229295-A1 | Amide derivatives | ASTELLAS PHARMA INC.AND RATIONAL DRUG DESIGN (JP) | 2006-10-12 | — | — | US | disclosed |
| EP-1652843-A1 | AMIDE DERIVATIVES | Astellas Pharma Inc. (JP) | 2006-05-03 | — | — | EP | disclosed |
| US-6949543-B2 | Amide derivative | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2005-09-27 | — | — | US | disclosed |
| EP-1340750-B1 | AMIDE DERIVATIVES | YAMANOUCHI PHARMA CO LTD (JP) | 2005-08-17 | — | — | EP | disclosed |
| US-6903125-B2 | Tetrahydro-2H-thiopyran-4-carboxamide derivative | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2005-06-07 | — | — | US | disclosed |
| US-20050032855-A1 | Tetrahydro-2H-thiopyran-4-carboxamide derivative | YAMANOUCHI PHARMACEUTICAL CO., LTD. | 2005-02-10 | — | — | US | disclosed |
| US-20040034232-A1 | Amide derivative | ASTELLAS PHARMA INC. (JP) | 2004-02-19 | — | — | US | disclosed |
| EP-1340750-A1 | AMIDE DERIVATIVES | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2003-09-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048310-A1 | AGENT FOR PREVENTION/TREATMENT OF DISEASE CAUSED BY ACYCLOVIR-RESISTANT HERPESVIRUS | ZC3HAV1, ZC3HAV1L, GRIK2 | LMNA 4141/4885FFAR1 3511/4885FFAR4 2983/4885 |
| US-20040034232-A1 | Amide derivative | HDAC2, ZC3HAV1, HDAC4 | LMNA 4369/4885FFAR1 3721/4885FFAR4 2442/4885 |
| US-20050032855-A1 | Tetrahydro-2H-thiopyran-4-carboxamide derivative | TPMT, RPL35, TYMP | LMNA 4689/4885FFAR1 4128/4885FFAR4 3251/4885 |
| US-20060229295-A1 | Amide derivatives | VAC14, HDAC8, ZC3HAV1 | LMNA 4538/4885FFAR1 3712/4885FFAR4 3635/4885 |
| US-20090042915-A1 | PREVENTIVE OR THERAPEUTIC AGENT FOR HERPESVIRUS-RELEATED DISEASE | RECQL, DNA2, DHX35 | LMNA 1226/4885FFAR1 4749/4885FFAR4 4858/4885 |
| US-20090030049-A1 | MEDICAMENT FOR GENITAL HERPES | TK1, TYMP, RPL23 | LMNA 4643/4885FFAR1 3791/4885FFAR4 2974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.